《新股表現》再鼎醫藥(09688.HK)高開9.2%報613.5元
再鼎醫藥(09688.HK)暗盤平開報562元獲承接,最高見586.5元,收582.5元高上市價3.7%;該股首掛開報613.5元,較上市價562元,高近9.2%,市前成交27.6萬股。
再鼎醫藥(ZLAB.US)上周五於美股續升2.9%收79.33美元。
中概股再鼎醫藥總部位於上海,是一間創新型、立足研發及處於商業階段生物製藥公司,其致力於為全球患者生產包括腫瘤、抗感染及自體免疫性疾病領域的創新藥物。該股已於2017年9月在納指上市,今次來港作第二上市合共發售約1,056.41萬股,其中約7.3%開發售獲2.43倍超購,認購一手中籤率50%;股份最終定價562元(招股最高發售價648元),料集資淨額約57.3億元,主要用作研發核心產品、為進行中和計劃臨床試驗及管線中其他候選藥物的準備中註冊備案撥資、探索新的全球授權和合作機會等、用作持續投資和擴大公司內部研發產品管線及在全球招聘培訓高端人才等。上市聯席保薦人分別為摩通、高盛及花旗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.